Insight journal - Dealtalk

Meda Cash Flow Invites Pipeline pharma deals at 95% Discount

Posted on 23 May 2012

Tags: ,

Meda, Sweden's biggest publicly traded drugmaker, is offering one of the best pharma deals in the world for pharmaceutical companies looking to replenish their pipelines by swallowing up rivals.

As of yesterday, the $2.78 billion company was trading at 5.4 times its projected cash flow in 2013, cheaper than 95 percent of specialty drug companies with market values larger than $1 billion, according to data compiled by Bloomberg.

Meda was also valued at a discount of more than 70 percent to its competitors relative to sales and net assets, the data show.

Read the full article at Bloomberg (link no longer available)

 

Related

Read: more on dealtalk in pharma, biotech, life science partnering deal news, insights and glossary

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply

 

cabannerad300x150new4gif
rauconbadgejpg
e78banner300x150animgif
cpbannerad300x150new2gif
rauconbadgejpg
e78banner300x150animgif